[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-408125-105":59,"doc-detail-408125-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hiv-associated-sensory-neuropathy-current-progress-and-future-challenges","HIV-associated sensory neuropathy: current progress and future challenges","","Currently, no FDA-approved treatments exist to manage HIV-associated sensory neuropathy (HIV-SN), leaving care largely dependent on adjusting antiretroviral therapy (ART) dosing and medications. This review surveys recent advances in understanding HIV-SN, highlighting progress in the HIV-SN mouse model and intraepidermal nerve fiber denervation. It summarizes neurotoxic adverse effects of ART and examines synergy between HIV-SN and ART in peripheral neuropathy pathogenesis, while noting that further mechanism discovery is needed for chronic disease management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hiv-associated-sensory-neuropathy-current-progress-and-future-challenges/408125/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hiv-associated-sensory-neuropathy-current-progress-and-future-challenges/408125.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Are there FDA-approved treatments for HIV-associated sensory neuropathy (HIV-SN)?","Question",{"text":112,"@type":113},"No. The review states that currently there are no FDA-approved treatments to manage HIV-SN, so management is largely limited to adjusting ART dosing and medications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the review highlight about recent progress in understanding HIV-SN?",{"text":117,"@type":113},"It emphasizes advances in the HIV-SN mouse model and discusses intraepidermal nerve fiber denervation as important factors for understanding disease mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"How does antiretroviral therapy (ART) relate to HIV-SN and peripheral neuropathy?",{"text":121,"@type":113},"The review summarizes neurotoxic side effects of ART and explores interactions and synergy between HIV-SN and ART in peripheral neuropathy pathogenesis, indicating ART may counterproductively induce sensory neuropathy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},408125,1790893260,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Review Article  \nIsaac J. Gamez, Ajay Pal, Connor Haines and Subo Yuan*  \nHIV-associated sensory neuropathy: current progress and future challenges  \n[https://doi.org/10.1515/nipt-2025-0010](https://doi.org/10.1515/nipt-2025-0010)  \nReceived August 5, 2025; accepted November 25, 2025; published online December 11, 2025  \nAbstract: Currently, no US Food and Drug Administrationapproved treatments exist to manage HIV-associated sensory neuropathy (HIV-SN) and management is largely confined to adjusting antiretroviral therapy (ART) doses and medications. Thus, this urgent health crisis requires strong research commitment to identify a cure or palliative treatment. This review explores the current state-of-the-art related to HIV-SN. It first explores recent developmentsin the understanding of HIV-SN, emphasizing the importance of developmentsin the HIV-SN mouse model and nonmyelination intra epidermal never fiber denervation. Next, the neurotoxic side effects of ART are summarized. Finally, we explore the interactions and synergy between HIV-SN and ART in the pathogenesis of peripheral neuropathy. While the overall mortality related to HIV has decreased significantly in recent decades, further elucidation of the exact mechanisms of HIV-SN is needed to better treat patients living with HIV as a chronic condition.  \nKeywords: HIV; pain; pathways; neuropathy; HIV-associated sensory neuropathy; antiretroviral therapy  \nIntroduction  \nBy the end of 2023, the Joint United Nations Programme on HIV/AIDS and the World Health Organization reported  \n*Corresponding author: Subo Yuan, MD, PhD, Department of Neurobiology, University of Texas Medical Branch, Galveston, TX, USA and Institute for Human Infections and Immunity (IHII), University of Texas Medical Branch, Galveston, TX, 77555, USA, E-mail: [suyuan@utmb.edu](suyuan@utmb.edu).  \n[https://orcid.org/0000-0001-6093-5666](https://orcid.org/0000-0001-6093-5666)  \nIsaac J. Gamez and Connor Haines, John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA  \nAjay Pal, Department of Neurobiology, University of Texas Medical Branch, Galveston, TX, USA  \nthat an estimated 39.9 million people worldwide live with HIV [1] . Global access to antiretroviral therapy (ART) has turned HIV infection from a deadly disease into a controllable, chronic disease and closed the gap in lifespan between people living with HIV infection (PLWH) and the general population [2] . Unfortunately, the prevalence of HIV associated pain (HIV-PAIN) does not dramatically decrease when ART has effectively suppressed the HIV viral viremia [3]. The presence of under-addressed HIV-PAIN, including HIV associated sensory neuropathy (HIV-SN), is demoralizing, dulls quality of life and, importantly, disrupts ART adherence [4] .  \nThe difficulties of chronic HIV infection are not only related to immune deficiency but also to neurological sequelae such as peripheral neuropathy, cerebrovascular disease, and neurocognitive impairment [5–7] . In the progression of HIV infection, there is an increased risk of HIV-SN due to residual viral mediated neuroinflammation [8–12] . HIV-SN ranges in clinical presentation from numbness and tingling all the way to debilitating neuropathic pain that can interfere with activities of daily living, resulting in social consequences such as unemployment [13, 14] . Furthermore, the utilization of ART to treat HIV counterproductively induces sensory neuropathy through neurotoxic side effects [15–17] . Indeed, HIV-SN hasan estimated 30–60 % prevalence in HIV infected patients, varying by countries and region [18] . For example, some estimates of HIV-SN areas low as 8.6 %[16] in the United States and as high as 42 %[19] in Australia. High prevalence of disease is reported in African countries with rates reaching as high as36 %[20]. The cause of discrepancy between countries is multifactorial as delays in diagnosis, access to newer antiviral medications, and opportunistic infection rates d","cbCainsypOOjjiK0","https://ap.wps.com/l/cbCainsypOOjjiK0","pdf",918188,13,"English","# Introduction\n# Abnormal nociception\n# HIV-associated sensory neuropathy (HIV-SN)","[{\"question\":\"Are there FDA-approved treatments for HIV-associated sensory neuropathy (HIV-SN)?\",\"answer\":\"No. The review states that currently there are no FDA-approved treatments to manage HIV-SN, so management is largely limited to adjusting ART dosing and medications.\"},{\"question\":\"What does the review highlight about recent progress in understanding HIV-SN?\",\"answer\":\"It emphasizes advances in the HIV-SN mouse model and discusses intraepidermal nerve fiber denervation as important factors for understanding disease mechanisms.\"},{\"question\":\"How does antiretroviral therapy (ART) relate to HIV-SN and peripheral neuropathy?\",\"answer\":\"The review summarizes neurotoxic side effects of ART and explores interactions and synergy between HIV-SN and ART in peripheral neuropathy pathogenesis, indicating ART may counterproductively induce sensory neuropathy.\"}]","HIV-associated sensory neuropathy: current progress and future challenges | PDF",1790578365,33]